Ent-naive patients: randomized, openlabel pilot study. J Acquir Immune Defic SyndrEnt-naive patients: randomized, openlabel pilot

Ent-naive patients: randomized, openlabel pilot study. J Acquir Immune Defic Syndr
Ent-naive patients: randomized, openlabel pilot study. J Acquir Immune Defic Syndr 2013, 62:164?70. Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, Qaqish R, Tian M, Fredrick L, Podsadecki T, Norton M, Nilius A: Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses 2013, 29:256?65. Taiwo B, Swindells S, JC-1 price Berzins B, Acosta E, Ryscavage P, Lalezari J, Castro J, Adeyemi O, Yip B, Rathert M, Kuritzkes D, Eron J, MIDAS Study Team: Week 48 results of the Maraviroc Plus Darunavir/ritonavir Study (MIDAS) for treatment-naive patients infected with R5-tropic HIV-1 [Abstract TUPE099]. In 19th International AIDS Conference. Washington, DC (USA); July 2012. Bedimo R, Drechsler H, Turner D, Moore T, Ghormley J, Jain M, Petersen T, Santos M, Farukhi I, Cutrell J: RADAR study: Raltegravir combined with 656 boosted Darunavir has similar PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26240184 safety and antiviral efficacy as tenofovir/ emtricitabine combined with boosted darunavir in antiretroviral-na e patients [Abstract MOPE214]. In 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Rome (Italy); July 2011. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, et al: Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1infected patients (ACTG A5262). AIDS 2011, 25:2113?122. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, et al: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008, 358:2095?106. Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, Raffi F, Benetucci J, Mancini M, Yang R, Wirtz V, et al: A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV Clin Trials 2012, 13:119?30. Taiwo B, Acosta EP, Ryscavage P, Berzins B, Lu D, Lalezari J, Castro J, Adeyemi O, Kuritzkes DR, Eron JJ, et al: Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. J Acquir Immune Defic Syndr 2013, 64:167?73. The GARDEL Study Team: Dual therapy with Lopinavir/ Ritonavir (LPV/r) and Lamivudine (3TC) is non-inferior to standard triple drug therapy in Na e HIV-1 infected subjects: 48-week results of the GARDEL Study [Abstract LBPS7/6]. In 14th European AIDS Conference. Brussels (Belgium); Sept. 2013. Hill A, Sawyer W, Gazzard B: Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25681438 HIV Clin Trials 2009, 10:1?2. Achhra AC, Amin J, Hoy J, Tanuma J, Sirisanthana T, Nolan D, Merati T, Giles M: Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australia. AIDS Res Treat 2012, 2012:246280. Sax P: MODERN Study Stopped: An NRTI-Sparing, Two-Drug Initial Regimen Disappoints Again. Available at http://blogs.jwatch.org/hiv-id-observations/ index.php/modern-study-stopped-an-nrti-sparing-two-drug-initial-regimendisappoints-again/2013/10/14/. Accessed on 30 October 2013. Achhra AC, Boyd M, Law MG, Matthews G, Kelleher AD, Cooper DA: Sequencing antiretroviral therapy to maximize patient safety: could wemove away from Ritonavir, Abacavir, Tenofovir, and Efavirenz(.